BE795970A - Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant - Google Patents
Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenantInfo
- Publication number
- BE795970A BE795970A BE795970DA BE795970A BE 795970 A BE795970 A BE 795970A BE 795970D A BE795970D A BE 795970DA BE 795970 A BE795970 A BE 795970A
- Authority
- BE
- Belgium
- Prior art keywords
- quinoleine
- quinoxaline
- quinazoline
- pharmaceutical composition
- composition containing
- Prior art date
Links
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 2
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical class C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919672A GB1381979A (en) | 1972-02-29 | 1972-02-29 | Amino derivatives of quinoline quinoxaline and quinazoline |
| GB5162972 | 1972-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE795970A true BE795970A (fr) | 1973-08-27 |
Family
ID=26242776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE795970D BE795970A (fr) | 1972-02-29 | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US3890319A (fr) |
| JP (2) | JPS5754516B2 (fr) |
| AR (1) | AR213705A1 (fr) |
| AU (1) | AU471598B2 (fr) |
| BE (1) | BE795970A (fr) |
| CA (1) | CA981678A (fr) |
| CH (2) | CH577500A5 (fr) |
| DE (1) | DE2309160A1 (fr) |
| ES (2) | ES411804A1 (fr) |
| FI (1) | FI63757C (fr) |
| FR (1) | FR2181776B1 (fr) |
| GB (1) | GB1381979A (fr) |
| IE (1) | IE37519B1 (fr) |
| MX (1) | MX3042E (fr) |
| NL (1) | NL159102B (fr) |
| SE (1) | SE417204B (fr) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1463520A (en) * | 1974-09-06 | 1977-02-02 | Pfizer Ltd | Process for the production of imidazolines |
| JPS5373571A (en) * | 1976-12-10 | 1978-06-30 | Otsuka Pharmaceut Co Ltd | Carbostyril derivatives |
| JPS542338A (en) | 1977-04-22 | 1979-01-09 | Sandoz Ag | Pharmaceutical composition |
| US4188393A (en) | 1977-04-22 | 1980-02-12 | Sandoz Ltd. | Treating spastic conditions or relaxing muscles |
| FR2449087A2 (fr) * | 1979-02-16 | 1980-09-12 | Rhone Poulenc Ind | Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US4486432A (en) * | 1982-09-30 | 1984-12-04 | Eli Lilly And Company | Quinoxalinedione leukotriene release inhibitors |
| FR2541680B1 (fr) * | 1983-02-24 | 1985-06-14 | Rhone Poulenc Sante | Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent |
| JPS6118950U (ja) * | 1984-07-10 | 1986-02-03 | 財団法人鉄道総合技術研究所 | トロリ線の給油装置 |
| GB8827820D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| US5180721A (en) * | 1989-05-22 | 1993-01-19 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
| US5281591A (en) * | 1989-05-22 | 1994-01-25 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
| US5112822A (en) * | 1989-10-12 | 1992-05-12 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5231096A (en) * | 1989-10-12 | 1993-07-27 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5077292A (en) * | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
| US5204347A (en) * | 1989-10-12 | 1993-04-20 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines |
| US5326763A (en) * | 1989-10-12 | 1994-07-05 | Allergan, Inc. | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| US5198442A (en) * | 1989-10-12 | 1993-03-30 | Allergan, Inc. | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same |
| US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
| US5215991A (en) * | 1990-01-26 | 1993-06-01 | Allergan, Inc. | Combination of selective alpha-adrenergic agonists and Na+ /H+ ex |
| US5130441A (en) * | 1990-02-06 | 1992-07-14 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
| US5237072A (en) * | 1990-02-06 | 1993-08-17 | Allergan, Inc. | Method for producing amino-2-imidazoline derivatives |
| US5252595A (en) * | 1990-02-28 | 1993-10-12 | Allergan, Inc. | Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines |
| US5091528A (en) * | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
| US6323204B1 (en) * | 1993-10-13 | 2001-11-27 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| ES2187533T3 (es) * | 1993-10-13 | 2003-06-16 | Allergan Inc | Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina. |
| US5580892A (en) * | 1993-10-22 | 1996-12-03 | Allergan | Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US5576437A (en) * | 1993-12-17 | 1996-11-19 | The Procter & Gamble Company | 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists |
| PT735877E (pt) * | 1993-12-17 | 2000-12-29 | Procter & Gamble | Compostos de 6-(2-imidazolinilamino)quinoxalina uteis como agonistas do receptor alfa-2 adrenergico |
| US5578607A (en) * | 1993-12-17 | 1996-11-26 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| BR9408335A (pt) * | 1993-12-17 | 1997-08-19 | Procter & Gamble | Composto uso do mesmo e composição farmacêutica |
| KR100218978B1 (ko) * | 1994-02-08 | 1999-09-01 | 제임스 에이. 아르노 | 클로니딘 유도체의 제조방법 |
| AU704972B2 (en) | 1994-08-04 | 1999-05-13 | H. Lundbeck A/S | Novel benzimidazole derivatives |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5916900A (en) | 1995-06-29 | 1999-06-29 | The Procter & Gamble Company | 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| AU5433898A (en) * | 1996-11-25 | 1998-06-22 | Procter & Gamble Company, The | 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists |
| HUP0002966A3 (en) * | 1996-11-25 | 2001-10-29 | Procter & Gamble | 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists |
| IL130024A (en) * | 1996-11-25 | 2002-12-01 | Procter & Gamble | Compounds-2 Imidazoline and laminoindole Useful as agonists a - 2 - Adrenoceptors and pharmaceutical preparations containing them |
| US6306877B1 (en) | 1999-08-09 | 2001-10-23 | The Procter & Gamble Co. | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| US6172095B1 (en) | 1996-11-25 | 2001-01-09 | The Procter & Gamble Company | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists |
| JP2001506600A (ja) | 1996-11-25 | 2001-05-22 | ザ プロクター アンド ギャンブル カンパニー | α―２アドレナリン受容体作動薬として有用なグアニジニル複素環式化合物 |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| RU2193562C2 (ru) | 1997-11-24 | 2002-11-27 | Дзе Проктер Энд Гэмбл Компани | Производное 5-(2-имидазолиниламино)бензимидазола, фармацевтическая композиция |
| US6242442B1 (en) | 1998-12-17 | 2001-06-05 | Alcon Laboratories, Inc. | Brinzolamide and brimonidine for treating ocular conditions |
| BR0109317A (pt) * | 2000-07-14 | 2003-06-17 | Allergan Inc | Composições contendo componentes agonistas alfa-2-adrenérgicos |
| US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US20050026924A1 (en) * | 2000-07-14 | 2005-02-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| DK2153819T3 (da) * | 2000-07-14 | 2012-12-03 | Allergan Inc | Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat |
| US8858961B2 (en) | 2000-07-14 | 2014-10-14 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| DE10161767A1 (de) * | 2001-12-15 | 2003-06-26 | Merck Patent Gmbh | 2-Guanidino-4-heterocyclyl-chinazoline |
| US7030149B2 (en) | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
| US7642258B2 (en) * | 2002-04-19 | 2010-01-05 | Allergan, Inc. | Combination of brimonidine and timolol for topical ophthalmic use |
| WO2004032913A1 (fr) * | 2002-10-08 | 2004-04-22 | Allergan, Inc. | Agonistes des recepteurs adrenergiques alpha 2b ou 2b/2c pour le traitement de la neurodegenerescence |
| DE60318081T2 (de) * | 2002-10-08 | 2008-11-06 | Allergan, Inc., Irvine | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson |
| US20040191332A1 (en) * | 2003-03-27 | 2004-09-30 | Allergan, Inc. | Preserved ophthalmic compositions |
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| WO2005014046A2 (fr) | 2003-08-07 | 2005-02-17 | Allergan, Inc. | Compositions d'administration d'agents therapeutiques dans les yeux et leurs methodes d'elaboration et d'utilisation |
| US7452895B2 (en) * | 2003-08-14 | 2008-11-18 | Array Biopharma Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US20070042951A1 (en) * | 2003-10-08 | 2007-02-22 | Allergan, Inc. | Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides |
| ES2647618T3 (es) | 2004-05-25 | 2017-12-22 | Galderma Pharma S.A. | Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel |
| US7534795B2 (en) * | 2005-10-25 | 2009-05-19 | Allergan, Inc. | Compounds and their use related to compositions for treating disease |
| BRPI0618643A2 (pt) | 2005-11-09 | 2011-09-06 | Combinatorx Inc | composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso |
| BRPI0618668B1 (pt) | 2005-11-15 | 2021-09-21 | Array Biopharma Inc | Compostos inibidores dos receptores de tirosina quinase do tipo i, composições compreendendo tais compostos, e seus usos |
| WO2008074068A1 (fr) * | 2006-12-20 | 2008-06-26 | Prana Biotechnology Limited | Dérivés de quinoline substitués utilisés comme agents non-amyloïdogéniques |
| WO2008144399A1 (fr) * | 2007-05-18 | 2008-11-27 | Bausch & Lomb Incorporated | Complexes comprenant des agonistes du récepteur α2-adrénergique et compositions associées |
| US9192571B2 (en) * | 2008-03-03 | 2015-11-24 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
| US7842714B2 (en) * | 2008-03-03 | 2010-11-30 | Allergan, Inc. | Ketorolac tromethamine compositions for treating ocular pain |
| WO2011044229A1 (fr) | 2009-10-06 | 2011-04-14 | Allergan, Inc. | Dérivés de 2h-pyrrol-5-amine utilisés en tant que modulateurs des récepteurs alpha-adrénergiques |
| EP2329849B1 (fr) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combinaison d'un agoniste du récepteur alpha-2 adrénergique et d'un agent anti-inflammatoire non stéroïdien pour traiter ou empêcher un trouble cutané inflammatoire |
| US8394800B2 (en) | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
| AU2011231544B2 (en) | 2010-03-26 | 2015-01-15 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of telangiectasia |
| CA2792646C (fr) | 2010-03-26 | 2018-11-20 | Galderma Research & Development | Utilisations et compositions ameliorees pour un traitement sur et efficace de l'erytheme |
| AU2011237689A1 (en) | 2010-04-07 | 2012-11-08 | Allergan, Inc. | Combinations of preservatives for ophthalmic compositions |
| KR20130092957A (ko) | 2010-04-07 | 2013-08-21 | 알러간, 인코포레이티드 | 안과용 처방용 보존제 조성물의 조합 |
| CA2807084C (fr) | 2010-07-29 | 2018-05-22 | Allergan, Inc. | Solutions de brimonidine et de timolol sans conservateur |
| US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| JP2013540143A (ja) | 2010-10-21 | 2013-10-31 | ガルデルマ・ソシエテ・アノニム | ブリモニジンゲル組成物及び使用方法 |
| CA2843251A1 (fr) * | 2011-07-25 | 2013-01-31 | Santosh C. Sinha | Derives n-(imidazolidin-2-ylidene)quinoleines en tant que modulateurs des recepteurs alpha-2 adrenergiques |
| GR1009419B (el) | 2017-11-07 | 2018-12-14 | Φαρματεν Αβεε | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560501A (en) * | 1966-09-15 | 1971-02-02 | Ciba Geigy Corp | Process for making dihydroquinazolines |
| US3594380A (en) * | 1969-02-18 | 1971-07-20 | American Home Prod | Isoquinolin-1(2h)-ones |
| BE766039A (fr) * | 1971-04-21 | 1971-09-16 | Labofina Sa | Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres. |
-
0
- BE BE795970D patent/BE795970A/fr not_active IP Right Cessation
-
1972
- 1972-02-29 GB GB919672A patent/GB1381979A/en not_active Expired
-
1973
- 1973-02-08 AU AU51985/73A patent/AU471598B2/en not_active Expired
- 1973-02-13 SE SE7302024A patent/SE417204B/xx unknown
- 1973-02-14 IE IE236/73A patent/IE37519B1/xx unknown
- 1973-02-14 US US332485A patent/US3890319A/en not_active Expired - Lifetime
- 1973-02-14 FI FI436/73A patent/FI63757C/fi active
- 1973-02-15 MX MX129473U patent/MX3042E/es unknown
- 1973-02-20 ES ES411804A patent/ES411804A1/es not_active Expired
- 1973-02-21 JP JP48020280A patent/JPS5754516B2/ja not_active Expired
- 1973-02-22 CA CA164,361A patent/CA981678A/en not_active Expired
- 1973-02-23 AR AR246774A patent/AR213705A1/es active
- 1973-02-23 DE DE19732309160 patent/DE2309160A1/de active Pending
- 1973-02-27 ES ES412102A patent/ES412102A1/es not_active Expired
- 1973-02-28 CH CH149075A patent/CH577500A5/xx not_active IP Right Cessation
- 1973-02-28 FR FR7307157A patent/FR2181776B1/fr not_active Expired
- 1973-02-28 CH CH293873A patent/CH576975A5/xx not_active IP Right Cessation
- 1973-02-28 NL NL7302799.A patent/NL159102B/xx not_active IP Right Cessation
-
1980
- 1980-07-11 JP JP9493480A patent/JPS5625176A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| CH576975A5 (fr) | 1976-06-30 |
| AU471598B2 (en) | 1976-04-29 |
| NL7302799A (fr) | 1973-08-31 |
| JPS4897878A (fr) | 1973-12-13 |
| FI63757B (fi) | 1983-04-29 |
| GB1381979A (en) | 1975-01-29 |
| JPS5745439B2 (fr) | 1982-09-28 |
| ES411804A1 (es) | 1976-05-01 |
| FR2181776A1 (fr) | 1973-12-07 |
| AR213705A1 (es) | 1979-03-15 |
| AU5198573A (en) | 1974-08-08 |
| IE37519B1 (en) | 1977-08-17 |
| DE2309160A1 (de) | 1973-09-27 |
| FI63757C (fi) | 1983-08-10 |
| MX3042E (es) | 1980-03-04 |
| JPS5625176A (en) | 1981-03-10 |
| IE37519L (en) | 1973-08-29 |
| FR2181776B1 (fr) | 1976-08-13 |
| JPS5754516B2 (fr) | 1982-11-18 |
| SE417204B (sv) | 1981-03-02 |
| CA981678A (en) | 1976-01-13 |
| ES412102A1 (es) | 1976-05-16 |
| US3890319A (en) | 1975-06-17 |
| CH577500A5 (fr) | 1976-07-15 |
| NL159102B (nl) | 1979-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE795970A (fr) | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant | |
| BE804558A (fr) | Nouveaux derives de 2-amino- ou 4-amino-quinazoline et medicaments les contenant | |
| FR2279406A1 (fr) | Nouveaux derives de quinazoline et medicament les contenant | |
| BE787103A (fr) | Nouveaux derives de propanolamine et composition pharmaceutiqueles contenant | |
| BE855713Q (fr) | Nouveaux derives de 4-aminoquinoleine, leur procede de preparation et medicament les contenant | |
| BE750192A (fr) | Nouveaux derives de la quinazolinone, leur preparation et medicaments contenant ces derives | |
| BE811856A (fr) | Nouveaux derives de quinazoline et composition pharmaceutique les contenant | |
| BE746301A (fr) | Nouveaux benzylimidazoles alpha, alpha-disubstitues, leur procede de preparation et compositions pharmaceutiques les contenant | |
| BE802996R (fr) | Nouveaux derives de la 4-amino-quinazolines, leur preparation et medicaments contenant ces derives | |
| BE794226A (fr) | Derives de la quinoleine, leur preparation et les medicaments qui en contiennent | |
| BE746756A (fr) | Nouveaux derives de la 4-amino-quinazoline, leur preparation etmedicaments contenant ces derives | |
| BE803474A (fr) | Nouvelles 2-alkylamino-dihydropyridines, leur procede de preparation et compositions pharmaceutiques les contenant | |
| BE759176A (fr) | Derives de la pyrimidine, leur preparation et medicaments contenant cesderives | |
| FR2290193A1 (fr) | Derives de n2-naphtalenesulfonyl-l-arginine, leur preparation et compositions pharmaceutiques les contenant | |
| BE777911A (fr) | Nouveaux composes heterocycliques, leur preparation et compositions pharmaceutiques les contenant | |
| BE806854A (fr) | Nouvelles urees tricycliques, leur preparation et les compositions pharmaceutiques en contenant | |
| BE775294A (fr) | Nouveaux derives de la pyridazine, leur preparation et medicaments les contenant | |
| BE808094A (fr) | Nouveaux derives de propanolamine et composition pharmaceutique les contenant | |
| BE759842R (fr) | Nouveaux derives de la 4-amino-quinazoline, leur preparation etmedicaments contenant ces | |
| BE766588A (fr) | Derives de la piperazine, leur preparation et medicaments contenant cesderives | |
| BE803373A (fr) | Nouveaux derives de 1,4-benzene-disulfamide et composition pharmaceutique les contenant | |
| BE766587A (fr) | Derives de la piperazine, leur preparation et medicaments en contenant | |
| BE765443A (fr) | Nouveaux derives de la piperidine, leur preparation et medicaments contenant ces derives | |
| BE776315A (fr) | Nouveaux derives de la 1-amino-isoquinoleine, leur preparation et leur application comme medicaments | |
| BE744626A (fr) | Nouveaux derives de la pyridazine,leur preparation et medicaments contenant ces derives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: PFIZER CORP. Effective date: 19920228 |